Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SOL784
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : McQuade Center for Strategic Research and Development
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, MSRD and Sentinel will collaborate to support the Phase 1a and Phase 1b clinical trials for Sentinel’s investigational compound SOL784 with the opportunity to expand the collaboration after those studies.
Brand Name : SOL784
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : SOL784
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : McQuade Center for Strategic Research and Development
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SOL-578
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : PharmaEngine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the Agreement, Sentinel Oncology will receive an exclusivity payment and PharmaEngine will obtain an option to receive the exclusive rights to develop and commercialize SOL-578 worldwide.
Brand Name : SOL-578
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 04, 2020
Lead Product(s) : SOL-578
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : PharmaEngine
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?